Andrea Luk Selected Research

Type 2 Diabetes Mellitus (MODY)

1/2022	Neuronal Dysfunction Is Linked to the Famine-Associated Risk of Proliferative Retinopathy in Patients With Type 2 Diabetes.
1/2021	Use of sodium-glucose co-transporter-2 inhibitors in Asian patients with type 2 diabetes and kidney disease: An Asian perspective and expert recommendations.
1/2020	Use of SGLT-2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Abdominal Obesity: An Asian Perspective and Expert Recommendations.
1/2020	Age at diagnosis, glycemic trajectories, and responses to oral glucose-lowering drugs in type 2 diabetes in Hong Kong: A population-based observational study.
11/2019	Use of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus and multiple cardiovascular risk factors: An Asian perspective and expert recommendations.
1/2018	Depressive Symptoms, Co-Morbidities, and Glycemic Control in Hong Kong Chinese Elderly Patients With Type 2 Diabetes Mellitus.
6/2017	What next after basal insulin? Treatment intensification with lixisenatide in Asian patients with type 2 diabetes mellitus.
2/2017	Curvilinear associations of sleep patterns during weekdays and weekends with glycemic control in type 2 diabetes: the Hong Kong Diabetes Registry.
1/2016	Retinal Information is Independently Associated with Cardiovascular Disease in Patients with Type 2 diabetes.
1/2016	Gender, diabetes education, and psychosocial factors are associated with persistent poor glycemic control in patients with type 2 diabetes in the Joint Asia Diabetes Evaluation (JADE) program.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Andrea Luk Research Topics

Disease

12	Type 2 Diabetes Mellitus (MODY) 01/2022 - 04/2014
4	Body Weight (Weight, Body) 01/2021 - 03/2016
4	Hypoglycemia (Reactive Hypoglycemia) 11/2018 - 04/2014
3	Albuminuria 01/2021 - 04/2014
3	Neoplasms (Cancer) 01/2020 - 04/2014
2	Obesity 01/2022 - 01/2016
2	Heart Failure 01/2021 - 11/2019
2	Hyperglycemia 06/2017 - 05/2014
1	Starvation 01/2022
1	Kidney Diseases (Kidney Disease) 01/2021
1	Chronic Kidney Failure (Chronic Renal Failure) 01/2021
1	Disease Progression 01/2021
1	Virus Diseases (Viral Diseases) 01/2020
1	Weight Gain 01/2020
1	Chronic Hepatitis B 01/2020
1	Overweight 01/2020
1	Abdominal Obesity 01/2020
1	Vomiting 06/2017
1	Nausea 06/2017
1	Weight Loss (Weight Reduction) 03/2016
1	Prediabetic State (Prediabetes) 03/2016
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2016
1	Chronic Renal Insufficiency 04/2014

Drug/Important Bio-Agent (IBA)

7	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 02/2017
5	Insulin (Novolin)FDA Link 01/2020 - 05/2014
3	Sodium-Glucose Transporter 2 InhibitorsIBA 01/2021 - 11/2019
3	SodiumIBA 01/2021 - 11/2019
3	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 11/2018 - 04/2014
2	Retinaldehyde (Retinal)IBA 01/2022 - 01/2016
2	Blood Glucose (Blood Sugar)IBA 11/2019 - 05/2014
2	oxidized low density lipoproteinIBA 01/2018 - 04/2014
2	Triglycerides (Triacylglycerol)IBA 05/2014 - 04/2014
1	Hemoglobins (Hemoglobin)IBA 01/2022
1	RO7020531IBA 01/2020
1	ProdrugsIBA 01/2020
1	ThiazolidinedionesIBA 01/2020
1	Toll-Like Receptor 7IBA 01/2020
1	Biosimilar PharmaceuticalsIBA 11/2018
1	lixisenatideIBA 06/2017
1	Glucagon-Like Peptide-1 Receptor AgonistsIBA 06/2017
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 05/2014
1	Fibric Acids (Fibrates)IBA 05/2014
1	Metformin (Glucophage)FDA LinkGeneric 05/2014
1	2,4-thiazolidinedione (thiazolidinedione)IBA 05/2014
1	LDL CholesterolIBA 04/2014

Therapy/Procedure

5	Glycemic Control 01/2018 - 04/2014
2	Therapeutics 01/2021 - 01/2020
1	Secondary Prevention 11/2019
1	Bariatric Surgery 03/2016